Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyRon Ram, Ronen Ben‐Ami, David Hagin et al.|Transplantation and Cellular Therapy|2021Cited by 164
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studiesDan Cohen, Einat Even‐Sapir, Efrat Luttwak et al.|European Journal of Nuclear Medicine and Molecular Imaging|2021Cited by 58
Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cellsOfrat Beyar‐Katz, Ron Ram, Noam Benyamini et al.|European Journal Of Haematology|2021Cited by 41
Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experienceOfrat Beyar‐Katz, Ron Ram, Oleg Pikovsky et al.|Annals of Hematology|2022Cited by 31
Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort StudyRon Ram, David Hagin, Nili Eilaty et al.|Transplantation and Cellular Therapy|2022Cited by 14